Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1005362.RARYVctpNbuFTJtE7GjvhJ_awA4wqqSTtp1SZoqIvTMfk130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1005362.RARYVctpNbuFTJtE7GjvhJ_awA4wqqSTtp1SZoqIvTMfk130_assertion type Assertion NP1005362.RARYVctpNbuFTJtE7GjvhJ_awA4wqqSTtp1SZoqIvTMfk130_head.
- NP1005362.RARYVctpNbuFTJtE7GjvhJ_awA4wqqSTtp1SZoqIvTMfk130_assertion description "[Taking advantage of our recently identified novel selective antagonist for the EP2 (PTGER2) subtype of PGE(2) receptor, we demonstrated that EP2 receptor activation could promote prostate cancer cell growth and invasion in vitro, accompanied by upregulation of the tumor-promoting inflammatory cytokines, such as IL-1? and IL-6.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1005362.RARYVctpNbuFTJtE7GjvhJ_awA4wqqSTtp1SZoqIvTMfk130_provenance.
- NP1005362.RARYVctpNbuFTJtE7GjvhJ_awA4wqqSTtp1SZoqIvTMfk130_assertion evidence source_evidence_literature NP1005362.RARYVctpNbuFTJtE7GjvhJ_awA4wqqSTtp1SZoqIvTMfk130_provenance.
- NP1005362.RARYVctpNbuFTJtE7GjvhJ_awA4wqqSTtp1SZoqIvTMfk130_assertion SIO_000772 23192657 NP1005362.RARYVctpNbuFTJtE7GjvhJ_awA4wqqSTtp1SZoqIvTMfk130_provenance.
- NP1005362.RARYVctpNbuFTJtE7GjvhJ_awA4wqqSTtp1SZoqIvTMfk130_assertion wasDerivedFrom befree-20150227 NP1005362.RARYVctpNbuFTJtE7GjvhJ_awA4wqqSTtp1SZoqIvTMfk130_provenance.
- NP1005362.RARYVctpNbuFTJtE7GjvhJ_awA4wqqSTtp1SZoqIvTMfk130_assertion wasGeneratedBy ECO_0000203 NP1005362.RARYVctpNbuFTJtE7GjvhJ_awA4wqqSTtp1SZoqIvTMfk130_provenance.